Apollo Hospitals Enterprise Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Healthcare Services leads with 17% YoY growth, driven by volumes, network expansion, and rising private insurance penetration; the company targets over 15% growth in FY25.
• Margins dipped on deliberate investment: Healthcare Services EBITDA margin at 23.1% reflects 150 new doctor hires and a one-time IT cost reset; management expects a 150 bps expansion and a 25% quarterly exit rate by year-end.
• Apollo 24/7 is on a defined path to breakeven within 6–8 quarters, targeting ₹1,700 crore GMV and an 8% take rate, up from 4% today.
• The Supreme Court ruling on hospital pricing was a positive outcome for the private sector, affirming rates are a function of market dynamics where input costs cannot be controlled.
• What to watch next quarter: The pace of margin recovery as new doctor hires begin contributing fully, the trajectory of 24/7’s GMV and take rate, and occupancy gains in underperforming regions like AP/Telangana and the Western region.

Healthcare Services: Growth & Margins

• Volume-led growth: 17% YoY revenue growth came from higher patient volumes, better asset utilization, and network expansion, with private insurance penetration enabling patients from smaller nursing homes to enter the Apollo system.
• Payer mix strengthening: Cash and insurance revenues now constitute 82% of inpatient revenue; international patients are at 7% of total revenue but reach 20% in Delhi, with a target to improve to 10% overall.
• Occupancy at 65%: Achieved despite a marginal reduction in average length of stay and recalibration of some beds for focused specialty clinical requirements; the budget targets 68–70% occupancy for the current year.
• Margin dip was a choice, not a drift: The 23.1% Healthcare Services margin reflects curated investments in 150 new doctors and enhanced sales and marketing costs, plus a one-time IT expense reset from cloud migration and a provider change.
• Regional occupancy drag: AP/Telangana has two smaller hospitals at ~50% occupancy versus Jubilee Hills at 70%; the Western region is weighed down by Nasik, a small market with multiple players where Apollo is not investing and only aiming for breakeven.

A Krishnan: "The new doctors hire, obviously, it's a clear decision to hire doctors to improve revenues and increase them in specific specialties, and that's started playing already, but we will see a fuller benefit of it by Q2."

Apollo HealthCo & Digital: The Breakeven Path

• Apollo 24/7 breakeven commitment: Management committed to achieving breakeven for the digital business within AHLL in the next 6 to 8 quarters.
• GMV target of ₹1,700 crore: The target composition is 55% pharmacy, 10% from newer segments like digital therapeutics and insurance, with the rest from diagnostics and consultations.
• Take rate to double: The current 4% commission take rate is expected to rise to 8% in 6 to 7 quarters, a critical lever for breakeven.
• Cost discipline built in: If volumes come in lower, management plans to rationalize and optimize expenses and will look extensively at the payer mix.
• Offline pharmacy still growing: The business plans to add 500–550 stores in the current fiscal year and expects 20–21% growth in the offline business, with front-end growth factored at ~22%.
• Q4 pharmacy slowdown explained: Growth was below the run rate due to conscious store-level stock rationalization; a ₹150 crore delta in front-end stock versus the prior year reduced back-end distribution sales.

Sanjiv Gupta: "Now, we are also mindful to the fact that, this is Plan A that you get into a topline of about INR 1,700 crore of GMV. And the current take rate, if you look at this, is about 4%, which is the commission that we call it. And the 4% will go up to 8% in 6 to 7 quarters from now."

AHLL & Specialty Care: Margin Turnaround Underway

• AHLL margin jump: Margins improved to 10.1% from 8.3% in Q4 FY23, and further to 10.8% for the full year, a 3.2 percentage point improvement driven by higher volumes, tightened unit economics, and a 3% gross margin improvement from changing methodology from dry to wet.
• AHLL revenue momentum: The business is cycling 20% growth for the third year in a row and management is confident of sustaining that topline rate at better margin levels, targeting mid-teens margins this financial year.
• Specialty Care margin swing explained: Q4 margin dropped to ~5% from 13% sequentially because four centers (Electronic City, Rajajinagar, Indirapuram) carried only costs as relaunches or launches in FY24 with no revenue, plus two relocations (Jaipur, Pusa Road) had minimal revenue; the fixed cost drag was almost ₹29 crore.
• Delhi centre margins understated: Reported margins of 15–15.5% reflect a lot of free work; if added back, margins would be 24–27%.
• FY25 recovery expected: Specialty Care will have revenues for the full year in FY25, with the major part of the year seeing revenue contribution.

Network Expansion & New Hospitals

• Four new hospitals with 1,500 beds: Planned to go live in existing markets — Gurgaon (anchor for NCR), Kolkata, Hyderabad, and Pune — within calendar year 2025 to 2026.
• Doctor hiring de-risked: Key doctors for all specialties have been identified and are getting trained within their core, giving management confidence of faster breakeven for the new hospitals.
• Recent additions: Beds added in Indore and Rourkela, with Rourkela already operationalized and contributing to Q4 numbers; Lucknow added about 40 beds in the Northern region; the Ahmedabad facility, previously a 50:50 JV, has been bought over and consolidated.
• Delhi centre expansion: Plans to add 100 beds over approximately two years, with capex including a ZAP machine and parking creation to be compliant for additional beds; government approval for capex is in place as it is a JV.
• Most new facilities by Q4: One could slip into Q1 of the following year.

Regulatory & Industry Context

• Supreme Court ruling favorable: The Court stated that hospital rates are a function of market rates and that where input costs, specifically doctor fees, cannot be controlled, pricing cannot be fixed; the Government is to return on September 10. Management called it a "very good outcome for the private sector."
• New procedures now insured: Robotic surgeries, digital therapeutics, stem cell procedures, oncology procedures, and neuro-guided navigation have been added under new regulations, expanding the addressable insured market.
• CGHS rate revision possible: Apollo’s exposure to CGHS is very limited, but if CGHS rates go up, there is a possibility of benefit.

Suneeta Reddy: "The Supreme Court said that hospital rates are a function of market rates. And in a place where you cannot, in a market where you cannot control the input rates, specifically calling out doctor fees, you cannot really put a fix on what the pricing should be."

Guidance & Commitments

Key Metrics